217 related articles for article (PubMed ID: 27020170)
1. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Harbeck N; Lipatov O; Frolova M; Udovitsa D; Topuzov E; Ganea-Motan DE; Nakov R; Singh P; Rudy A; Blackwell K
Future Oncol; 2016 Jun; 12(11):1359-67. PubMed ID: 27020170
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
3. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
Blackwell K; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Harbeck N
Ann Oncol; 2017 Sep; 28(9):2272-2277. PubMed ID: 28637287
[TBL] [Abstract][Full Text] [Related]
4. Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials.
Harbeck N; Gascon P; Jones CM; Nixon A; Krendyukov A; Nakov R; Li Y; Blackwell K
Future Oncol; 2017 Jul; 13(16):1385-1393. PubMed ID: 28453299
[TBL] [Abstract][Full Text] [Related]
5. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
[TBL] [Abstract][Full Text] [Related]
6. LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM
BioDrugs; 2019 Apr; 33(2):229-232. PubMed ID: 30887256
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
[TBL] [Abstract][Full Text] [Related]
9. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
11. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
Botteri E; Krendyukov A; Curigliano G
Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.
Waller CF; Ranganna GM; Pennella EJ; Blakeley C; Bronchud MH; Mattano LA; Berzoy O; Voitko N; Shparyk Y; Lytvyn I; Rusyn A; Popov V; Láng I; Beckmann K; Sharma R; Baczkowski M; Kothekar M; Barve A
Ann Hematol; 2019 May; 98(5):1217-1224. PubMed ID: 30824956
[TBL] [Abstract][Full Text] [Related]
15. A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®).
Wong G; Zhang L; Majeed H; Razvi Y; DeAngelis C; Lam E; McKenzie E; Wang K; Pasetka M
J Oncol Pharm Pract; 2022 Jan; 28(1):5-16. PubMed ID: 33215563
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.
Kowalyszyn RD; Fein LE; Richardet ME; Varela MS; Ortiz E; Micheri C; Zarba JJ; Kahl S; Klimovsky E; Federico AA; Cassini JH; Cortese G; Lago N
JCO Glob Oncol; 2022 Mar; 8():e2100276. PubMed ID: 35324270
[TBL] [Abstract][Full Text] [Related]
17. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
Crawford J
Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.
Buchner A; Elsässer R; Bias P
Breast Cancer Res Treat; 2014 Nov; 148(1):107-16. PubMed ID: 25261291
[TBL] [Abstract][Full Text] [Related]
19. Filgrastim biosimilar (EP2006): A review of 15 years' post-approval evidence.
Gascón P; Harbeck N; Rapoport BL; Anderson R; Brueckmann I; Howe S; Aapro M
Crit Rev Oncol Hematol; 2024 Apr; 196():104306. PubMed ID: 38401695
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
